Literature DB >> 8751445

Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected].

O Planz1, P Seiler, H Hengartner, R M Zinkernagel.   

Abstract

In medically important infections with cytopathic viruses, neutralizing antibodies are generated within 6-14 days. In contrast, such protective antibodies appear late (50-150 days) after infection with immunodeficiency virus (HIV) and hepatitis B virus (HBV) in humans, or lymphocytic choriomeningitis virus (LCMV) in mice. However, during these infections, non-neutralizing antibodies appear much earlier. It has been proposed that T cells suppress antibody responses generally and against viruses in vitro. Here we show that the suppression of neutralizing-antibody-producing B cells by this non-cytopathic virus, and their subsequent destruction by virus-specific cytotoxic T cells. Such specific B-cell elimination that leads to a delay in neutralizing-antibody production could help to establish persistent virus infections by non-cytopathic viruses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751445     DOI: 10.1038/382726a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  37 in total

1.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 2.  Immune escape by hepatitis B viruses.

Authors:  U Protzer; H Schaller
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

3.  Antiviral immune responses in CTLA4 transgenic mice.

Authors:  C Zimmermann; P Seiler; P Lane; R M Zinkernagel
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Virus-specific CD4+ T cells eliminate borna disease virus from the brain via induction of cytotoxic CD8+ T cells.

Authors:  K Nöske; T Bilzer; O Planz; L Stitz
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 5.  Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view.

Authors:  S Abrignani
Journal:  Springer Semin Immunopathol       Date:  1997

6.  A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers.

Authors:  O Planz; S Ehl; E Furrer; E Horvath; M A Bründler; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

7.  In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model.

Authors:  T Cao; P Meuleman; I Desombere; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression.

Authors:  Ulf Dittmer; Brent Race; Karin E Peterson; Ingunn M Stromnes; Ronald J Messer; Kim J Hasenkrug
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

9.  Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.

Authors:  Lars Hangartner; Beatrice M Senn; Birgit Ledermann; Ulrich Kalinke; Peter Seiler; Etienne Bucher; Raphaël M Zellweger; Katja Fink; Bernhard Odermatt; Kurt Bürki; Rolf M Zinkernagel; Hans Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

10.  Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.

Authors:  Daniele Accapezzato; Vittorio Francavilla; Marino Paroli; Marco Casciaro; Lucia Valeria Chircu; Agostino Cividini; Sergio Abrignani; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.